3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Neoplasm Metastasis
8
Lung Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms
6
Ovarian Neoplasms
5
Melanoma
5
Carcinoma, Renal Cell
5
Skin Neoplasms
4
Fallopian Tube Neoplasms
4
Carcinoma
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Mouth Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Laryngeal Neoplasms
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Interventions
Paclitaxel
2
tremelimumab
1
trastuzumab deruxtecan
1
poly ICLC
1
pembrolizumab
1
osimertinib
1
eribulin
1
durvalumab
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Radiotherapy
1
Peptides
1
Doxorubicin
1
Docetaxel
1
Carboplatin
1
Capecitabine
1
Bevacizumab
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Diabetes Mellitus, Insulin-Dependent, 12
×
cemiplimab
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled